Skip to content

Study · Systematic review · 2023

4 results

Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.

Stretton B, Kovoor J, Bacchi S, Chang S, Ngoi B, Murray T, Bristow TC, Heng J, Gupta A, Ovenden C, Maddern G, Thompson CH and 5 more

Show all authors

Heilbronn L, Boyd M, Rayner C, Talley NJ, Horowtiz M

Internal medicine journal21 Jun 2023Cited by 19 (Europe PMC)

PMID37189293 (opens in a new tab)DOI10.1111/imj.16126 (opens in a new tab)PepBankPUB-37189293
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide gave more weight loss than other GLP-1 receptor agonists in randomised trials.

    In plain wordsIn adults with type 2 diabetes, injected semaglutide led to more weight loss than other GLP-1 drugs in trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss vs other GLP-1 receptor agonists
    Study

    n: not reported in source

    Comparator
    Other GLP-1 receptor agonists
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.
    1 context sentence
    Summary · context
    Comparators included liraglutide, exenatide, dulaglutide and tirzepatide.
  2. 02HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, subcutaneous semaglutide gave less weight loss than tirzepatide in randomised trials.

    In plain wordsIn adults with type 2 diabetes, injected semaglutide led to less weight loss than tirzepatide in trials.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight loss vs tirzepatide
    Study

    n: not reported in source

    Comparator
    Tirzepatide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D, but tirzepatide is more effective than semaglutide.
    1 context sentence
    Summary · context
    Comparators included liraglutide, exenatide, dulaglutide and tirzepatide.
  3. 03HumanSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, randomised trials show tirzepatide is more effective than semaglutide for weight loss.

    In plain wordsIn adults with type 2 diabetes, trials show tirzepatide caused more weight loss than semaglutide.

    Peptide
    Tirzepatide
    Outcome
    IncreaseWeight loss with tirzepatide versus semaglutide
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    but tirzepatide is more effective than semaglutide.
    1 context sentence
    Summary · context
    This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health.

Studies that did not test the peptide alone1

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 04HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, randomised trials support greater weight loss with semaglutide than with other GLP-1 receptor agonists (liraglutide, exenatide, dulaglutide pooled).

    In plain wordsIn adults with type 2 diabetes, trials show semaglutide caused more weight loss than other GLP-1 drugs as a group.

    Peptide
    Liraglutide
    Outcome
    Not applicableWeight loss with semaglutide versus other GLP-1 RAs
    Study

    n: not reported in source

    Comparator
    Semaglutide
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Randomised trials support the superior efficacy of semaglutide over other GLP-1 RAs with respect to weight loss in T2D
    2 context sentences
    Summary · context
    Comparators included liraglutide, exenatide, dulaglutide and tirzepatide.
    Summary · context
    This review was conducted with the aim of summarising direct comparisons between subcutaneous semaglutide and other GLP-1 RAs in individuals with type 2 diabetes (T2D), particularly with respect to efficacy for inducing weight loss and improving other markers of metabolic health.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 39Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Versions 2 to 3

    9 Oct 2026, 03:07 UTC

    The same notice was added 2 times, first on 9 Oct 2026, 03:06 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.